Ruben Mesa, MD, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms.
Ruben Mesa, MD, director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms (MPNs).
Mesa says this is an exciting time for the treatment of patients with MPNs, particularly in patients with essential thrombocytopenia and polycythemia vera after data were presented at the 2019 American Society of Hematology Meeting. Long-acting interferons continue to play a role in this space and are superior to hydroxyurea in both the first- and second-line settings.
In terms of myelofibrosis, a number of robust therapies are under development, including novel combinations of JAK inhibitors, Mesa says. BET inhibitors, TGF-beta inhibitors, LSD1 inhibitors, among others are under development for use both in combination and also as single-agents. Overall, this is an exciting time with a lot of new agents and treatment strategies under development, Mesa concludes. Hypomethylating agents and others are likely to have benefit for patients with advanced MPNs, as well, he says.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More